Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Palmar plantar erythrodysesthesia pathophysiology

Introduction

Overview

Overview

The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood. It is thought that PPE is caused by direct toxic effect of the chemotherapeutic drugs against keratinocytes, excretion of the drugs in eccrine sweat glands, or type I allergic reaction. The pathological features of PPE are non-specific. However, since PPE involves a cytotoxic reaction primarily affecting keratinocytes, the histopathologic findings are similar to histologic manifestation of direct toxic reactions.

Pathophysiology

Pathophysiology

Pathogenesis

  • The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood.
  • Suggested explanations include:
  • Unique characteristics of the palms and the soles which justify their involvement as the preferred sites of involvement include: [2] [5] [6]
Microscopic Pathology

Microscopic Pathology

References

References

  1. ↑ J. E. Fitzpatrick. “The cutaneous histopathology of chemotherapeutic reactions”. Journal of cutaneous pathology. PMIDΒ 8468414.
  2. ↑ 2.0 2.1 Baack BR, Burgdorf WH (1991). “Chemotherapy-induced acral erythema”. J Am Acad Dermatol. 24 (3): 457–61. PMIDΒ 2061446.
  3. ↑ Hiromi Tsuboi, Kohzoh Yonemoto & Kensei Katsuoka. “A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature”. The Journal of dermatology. PMIDΒ 16361756.
  4. ↑ Perry, Michael (2012). Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBNΒ 9781451101454.
  5. ↑ W. S. Susser, D. L. Whitaker-Worth & J. M. Grant-Kels. “Mucocutaneous reactions to chemotherapy”. Journal of the American Academy of Dermatology. PMIDΒ 10071309.
  6. ↑ Yvonne Lassere & Paulo Hoff. “Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)”. European journal of oncology nursingΒ : the official journal of European Oncology Nursing Society. doi:10.1016/j.ejon.2004.06.007. PMIDΒ 15341880.
  7. ↑ 7.0 7.1 7.2 7.3 Cox GJ, Robertson DB (1986). “Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy”. Arch Dermatol. 122 (12): 1413–4. PMIDΒ 2947543.
  8. ↑ Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A (1985). “Distinctive acral erythema occurring during therapy for severe myelogenous leukemia”. Arch Dermatol. 121 (1): 102–4. PMIDΒ 3855356.
  9. ↑ Fitzpatrick JE (1993). “The cutaneous histopathology of chemotherapeutic reactions”. J Cutan Pathol. 20 (1): 1–14. PMIDΒ 8468414.
  10. ↑ Calista D, Landi C (1998). “Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?”. J Eur Acad Dermatol Venereol. 10 (3): 274–5. PMIDΒ 9643337.
  11. ↑ Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN (2006). “Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report”. J Clin Neuromuscul Dis. 7 (3): 128–32. doi:10.1097/01.cnd.0000211401.19995.a2. PMIDΒ 19078798.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]